Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma
Sign Up to like & getrecommendations! Published in 2019 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-019-0629-7
Abstract: Bortezomib/thalidomide/dexamethasone (VTD) induction therapy followed by autologous stem cell transplantation (ASCT) is one of the standard therapies for newly diagnosed multiple myeloma (NDMM). However, the appropriate depth of response to induction therapy and timing of… read more here.
Keywords: additional cycles; cycles vtd; four cycles; induction therapy ... See more keywords